A subtype of classical Hodgkin lymphoma with scattered Hodgkin and Reed-Sternberg cells and a nodular or less often diffuse cellular background consisting of small lymphocytes and with an absence of n...
Comprehensive, easy-to-understand information about this condition
How we create this content →The limited documentation surrounding Hodgkin's lymphoma, lymphocytic-histiocytic predominance is primarily due to its rarity, which affects fewer than 1 in 100,000 individuals. This rarity leads to fewer systematic clinical studies and a lack of comprehensive data on clinical features and genetic factors. Additionally, the overlap of symptoms with other types of Hodgkin lymphoma complicates accurate characterization and understanding of this specific subtype.
To navigate your care effectively, consider seeking a hematologist or oncologist with specific expertise in Hodgkin lymphoma. They can provide tailored treatment options and monitor your condition closely. Additionally, while there are no specific patient organizations identified for this subtype, resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can offer support and information. Participating in clinical trials may also be a valuable option to explore, as they can provide access to cutting-edge therapies and contribute to the understanding of this rare condition.
Currently, there is one FDA-approved orphan drug for Hodgkin's lymphoma, lymphocytic-histiocytic predominance: brentuximab vedotin. Additionally, there are five active clinical trials exploring various aspects of treatment for this condition. For more information on these trials, you can visit the ClinicalTrials.gov search page at https://clinicaltrials.gov/search?cond=Hodgkin's%20lymphoma%2C%20lymphocytic-histiocytic%20predominance. This ongoing research may provide new insights and potential treatment options in the future.
Actionable guidance for navigating care for Hodgkin's lymphoma, lymphocytic-histiocytic predominance
To navigate your care effectively, consider seeking a hematologist or oncologist with specific expertise in Hodgkin lymphoma. They can provide tailored treatment options and monitor your condition closely. Additionally, while there are no specific patient organizations identified for this subtype, resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can offer support and information. Participating in clinical trials may also be a valuable option to explore, as they can provide access to cutting-edge therapies and contribute to the understanding of this rare condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding Hodgkin's lymphoma, lymphocytic-histiocytic predominance is primarily due to its rarity, which affects fewer than 1 in 100,000 individuals. This rarity leads to fewer systematic clinical studies and a lack of comprehensive data on clinical features and genetic factors. Additionally, the overlap of symptoms with other types of Hodgkin lymphoma complicates accurate characterization and understanding of this specific subtype.
To navigate your care effectively, consider seeking a hematologist or oncologist with specific expertise in Hodgkin lymphoma. They can provide tailored treatment options and monitor your condition closely. Additionally, while there are no specific patient organizations identified for this subtype, resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can offer support and information. Participating in clinical trials may also be a valuable option to explore, as they can provide access to cutting-edge therapies and contribute to the understanding of this rare condition.
Currently, there is one FDA-approved orphan drug for Hodgkin's lymphoma, lymphocytic-histiocytic predominance: brentuximab vedotin. Additionally, there are five active clinical trials exploring various aspects of treatment for this condition. For more information on these trials, you can visit the ClinicalTrials.gov search page at https://clinicaltrials.gov/search?cond=Hodgkin's%20lymphoma%2C%20lymphocytic-histiocytic%20predominance. This ongoing research may provide new insights and potential treatment options in the future.
Actionable guidance for navigating care for Hodgkin's lymphoma, lymphocytic-histiocytic predominance
To navigate your care effectively, consider seeking a hematologist or oncologist with specific expertise in Hodgkin lymphoma. They can provide tailored treatment options and monitor your condition closely. Additionally, while there are no specific patient organizations identified for this subtype, resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can offer support and information. Participating in clinical trials may also be a valuable option to explore, as they can provide access to cutting-edge therapies and contribute to the understanding of this rare condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding Hodgkin's lymphoma, lymphocytic-histiocytic predominance is primarily due to its rarity, which affects fewer than 1 in 100,000 individuals. This rarity leads to fewer systematic clinical studies and a lack of comprehensive data on clinical features and genetic factors. Additionally, the overlap of symptoms with other types of Hodgkin lymphoma complicates accurate characterization and understanding of this specific subtype.
To navigate your care effectively, consider seeking a hematologist or oncologist with specific expertise in Hodgkin lymphoma. They can provide tailored treatment options and monitor your condition closely. Additionally, while there are no specific patient organizations identified for this subtype, resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can offer support and information. Participating in clinical trials may also be a valuable option to explore, as they can provide access to cutting-edge therapies and contribute to the understanding of this rare condition.
Currently, there is one FDA-approved orphan drug for Hodgkin's lymphoma, lymphocytic-histiocytic predominance: brentuximab vedotin. Additionally, there are five active clinical trials exploring various aspects of treatment for this condition. For more information on these trials, you can visit the ClinicalTrials.gov search page at https://clinicaltrials.gov/search?cond=Hodgkin's%20lymphoma%2C%20lymphocytic-histiocytic%20predominance. This ongoing research may provide new insights and potential treatment options in the future.
Actionable guidance for navigating care for Hodgkin's lymphoma, lymphocytic-histiocytic predominance
To navigate your care effectively, consider seeking a hematologist or oncologist with specific expertise in Hodgkin lymphoma. They can provide tailored treatment options and monitor your condition closely. Additionally, while there are no specific patient organizations identified for this subtype, resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can offer support and information. Participating in clinical trials may also be a valuable option to explore, as they can provide access to cutting-edge therapies and contribute to the understanding of this rare condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
Organizations with orphan designations or approved therapies for this disease